The Oral Drug Delivery Opportunity

• Drugs using new delivery technologies totaled $14B in 2002 and revenue potential expected to increase 500% over the next decade*

  • Oral considered best in class; generating the most revenue of all delivery routes ($7.4 B in 2002)*

• Opportunities for oral delivery:

  • Vaccines: 50K – 1M daltons
  • Erythropoietin (SP): 30K daltons
  • Human growth hormone: 22K daltons
  • Heparins: 6K-30K
  • Insulin: 6K

*Source: “Drug Delivery: Many Ways to Get There” presented at SRI 8th International Drug Delivery Technologies & Deal-Making Summit Conference, 9/16/03

Previous slide

Next slide

Back to first slide

View graphic version